Results
Cohance Lifesciences Q1 Revenue Declines 23% YoY
• Investor presentation details Q1 FY27 unaudited results with revenue of ₹4,223 Mn, a 23.1% YoY decline, and adjusted EBITDA of ₹92 Mn.
• Management outlines strategic initiatives including full owne
